Product
Teverelix
1 clinical trial
1 indication
Indication
Prostate AdenomaClinical trial
An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH Antagonist, in Participants With Advanced Prostate CancerStatus: Completed, Estimated PCD: 2022-12-05